LSV Asset Management Has $417.51 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

LSV Asset Management decreased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,455,957 shares of the specialty pharmaceutical company’s stock after selling 55,901 shares during the period. Jazz Pharmaceuticals comprises 0.9% of LSV Asset Management’s holdings, making the stock its 19th largest holding. LSV Asset Management’s holdings in Jazz Pharmaceuticals were worth $417,513,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Cardinal Capital Management boosted its position in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 81 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after acquiring an additional 83 shares in the last quarter. Fairbanks Capital Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after acquiring an additional 94 shares in the last quarter. Finally, Danske Bank A S boosted its position in shares of Jazz Pharmaceuticals by 33.3% during the 4th quarter. Danske Bank A S now owns 400 shares of the specialty pharmaceutical company’s stock worth $68,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Raymond James Financial reiterated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Leerink Partners increased their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. TD Cowen increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Friday, March 27th. Finally, Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.53.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the transaction, the senior vice president owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This trade represents a 15.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Norbert G. Riedel sold 3,415 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the transaction, the director directly owned 7,024 shares of the company’s stock, valued at $1,348,608. The trade was a 32.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 74,015 shares of company stock valued at $14,180,486. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $239.83 on Friday. The company has a market cap of $15.05 billion, a price-to-earnings ratio of -11,985.51, a PEG ratio of 0.43 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a 50 day simple moving average of $202.44 and a 200 day simple moving average of $179.99. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Research analysts predict that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.